Mar 09,2023

Bigfoot Biomedical Named to Fast Company’s “World’s Most Innovative Companies” List

Bigfoot Biomedical has been selected as one of Fast Company's 2023 “World’s Most Innovative Companies” in the medical device category. Fast Company is the world’s leading business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, creativity, and design.

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

Continuous Glucose Monitoring (CGM) Market Report 2023: Sector to Reach $16.69 Billion by 2028 at a 19.16% CAGR

The continuous glucose monitoring market is expected to grow at a CAGR of 19.16%, from an initial value of US$4.896 billion in 2021 to US$16.698 billion by 2028 according to the publisher of the report. The rising investments by companies operating in this segment to commercialize their products are also expected to push the demand for such devices.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Analysts receive update on Embecta insulin patch pump progress

Speaking to DDBN, Kurdikar explained why Embecta elects to remain quiet on the development of its insulin patch pump. The company is designing the patch pump to address the unmet needs of type 2 diabetes. He said those with type 2 diabetes require more insulin today than type 1. Because of this, the company designed the pump with an increased reservoir capacity. The first version will be an open-loop pump that will go through the FDA 510(k) regulatory review process. Embecta also has a closed-loop version under development to follow. That version features an embedded algorithm that requires Embecta to run a clinical study, the analysts wrote. Embecta dedicated roughly two-thirds of its R&D budget to patch pump development

PRODUCT

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Huge win for continuous glucose monitor (CGM) and insulin pump coverage for people with type 1 diabetes in Manitoba

On March 7, 2023, the government of Manitoba announced that it was investing $120 million in the Manitoba Pharmacare program in part to expand coverage of diabetes devices like insulin pumps and glucose monitors. The province said it will be expanding the program to include all adults who have been diagnosed with type 1 and type 2 diabetes and have a prescription. Prior to this investment, coverage for pumps in Manitoba stopped at age 18 and coverage for advanced glucose monitors stopped at age 25. This announcement comes after significant advocacy from the Manitoba T1D community, with support from JDRF Canada. With coverage of both insulin pumps and CGMs expanding, those living with T1D and can take advantage of integrations for a hybrid-closed loop (HCL) system, which acts as an artificial pancreas.

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Sweden Diabetes Market Report 2023: Featuring B. Braun Melsungen, Eli Lilly, Novo Nardisk, Becton, Dickinson, Medtronic & More

Sweden's Diabetes Market will reach US$ 1.86 Billion in 2028 and expand at a CAGR of 4.26% from 2023 to 2028, according to the publisher.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Global Sales Of Insulin Pumps Are Expected To Reach Us$ 13.34 Billion By 2032

As per industry analysis by Fact.MR, a market research and competitive intelligence provider, the global insulin pumps market is currently valued at US$ 6.18 billion and is predicted to expand rapidly at a CAGR of 8% from 2022 to 2032.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Blood Glucose Meters Market Predicted to Garner USD 22.6 Billion By 2032, At CAGR 8.7%

Global sales of blood glucose meters market were estimated to be worth USD 10 billion in 2022 and are slated to be worth USD 22.6 billion by 2032 to grow on an impulsive note at a CAGR of 8.7% from 2023 to 2033.

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 26,2022

A new partnership between SocialDiabetes and the University of Girona to implement AI-based Digital Therapies for diabetes management.

Extending their long-standing partnership, the MiceLab research group at the University of Girona and SocialDiabetes have announced a multi-year collaboration to provide people with diabetes and the professionals who treat them with AI-based predictive and personalization tools. The first phase of the project aims to provide patients with type 1 diabetes with multi-dose insulin therapy using smart pens with the same benefits as patients on automated insulin pump systems (artificial pancreas).

COLLABORATION PARTNERSHIP

#r&d

#insulin pen

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 25,2022

Diabetes:M Partners with aktivmed in Germany

aktivmed, a leading German glucometer manufacturer, joins the list of Sirma Medical Systems integration partners to provide better care for people with diabetes in Germany. The new partnership allows owners of aktivmed’s flagship product – the GlucoCheck GOLD Bluetooth-enabled meter, to connect it with Diabetes:M seamlessly.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Amalgam Rx’s DoseCheck Receives SFDA Clearance in Saudi Arabia

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, announced that our insulin titration solution, DoseCheck, will now help patients and their care teams manage their insulin and glucose in yet another country.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES